Evidence map›Paper›PMID 41887186›Full record

ArticleMediators of inflammation2026

Maresin 1 Ameliorates Diabetic Kidney Disease in Mice by Promoting Macrophage M2 Polarization.

Yueli Pu, Xiumei Ma, Kang Geng, Renliang Meng, Yonglin Li, Chunmei Zheng, Changying Zhao, Fangyuan Teng, Yong Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yueli PuDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, ahswmu.cn.ORCID https://orcid.org/0000-0003-0258-1235
Xiumei MaSichuan Provincial Key Laboratory for Human Disease Gene Study and Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610000, Sichuan, China, uestc.edu.cn.ORCID https://orcid.org/0000-0002-1433-8315
Kang GengDepartment of Plastic and Burns Surgery, National Key Clinical Construction Specialty, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, ahswmu.cn.ORCID https://orcid.org/0009-0008-7696-542X
Renliang MengDepartment of Neurology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, ahswmu.cn.ORCID https://orcid.org/0009-0005-5490-0690
Yonglin LiDepartment of Endocrinology and Metabolism, The Affiliated Traditional Chinese Medical Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, swmu.edu.cn.ORCID https://orcid.org/0009-0001-2360-2309
Chunmei ZhengDepartment of Endocrinology and Metabolism, The Affiliated Traditional Chinese Medical Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, swmu.edu.cn.ORCID https://orcid.org/0009-0004-6127-6243
Changying ZhaoDepartment of Endocrinology and Metabolism, The Affiliated Traditional Chinese Medical Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, swmu.edu.cn.ORCID https://orcid.org/0000-0002-2158-2447
Fangyuan TengDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, ahswmu.cn.ORCID https://orcid.org/0000-0002-9564-0961
Yong XuDepartment of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China, ahswmu.cn.ORCID https://orcid.org/0000-0002-9534-6252

Funding

Luzhou Science and Technology development grant 2024WGR205National Natural Science Foundation of China 82470854National Natural Science Foundation of China U22A20286 andNoncommunicable Chronic Diseases-National Scienceand Technology Major Project 2024ZD0531300Scientific research project of Southwest Medical University 2024LCYXZX02Sichuan Province Science and Technology Support Program 26ZRZZ0024
6 · The paper itself

Abstract

backgroundThe progression of diabetic kidney disease (DKD) is strongly associated with a chronic inflammatory microenvironment, with macrophage polarization imbalance recognized as a pivotal driver. Maresin 1 (MaR1), a specialized proresolving lipid mediator, plays a crucial role in restoring immune homeostasis across various inflammatory conditions. However, its precise role in ameliorating kidney injury through macrophage polarization in DKD remains unclear.

methodsThe type 2 diabetes mouse model was established using a high-fat diet combined with streptozotocin induction. The therapeutic efficacy of MaR1 was assessed by evaluating metabolic parameters (blood glucose, lipid profile), renal function (urine albumin-to-creatinine ratio [ACR], serum creatinine, and blood urea nitrogen [BUN]), and renal pathology (HE staining and Masson staining). In vitro, bone marrow-derived macrophages (BMDMs) were exposed to high glucose, and the modulatory effect of MaR1 on M1/M2 polarization was assessed using RT-qPCR, immunohistochemistry, and immunofluorescence.

resultsMaR1 treatment significantly ameliorated metabolic abnormalities in diabetic mice (lower blood glucose and cholesterol), improved renal function (reduced ACR, serum creatinine, and BUN), and attenuated renal fibrosis (all p  < 0.05). Mechanistically, MaR1 reversed macrophage polarization imbalance both in vivo and in vitro, promoting a shift from the M1 phenotype (downregulation of iNOS and TNF-α) to the M2 phenotype (upregulation of Arg-1 and IL-10).

conclusionMaR1 improves metabolic disturbances and renal injury in DKD by driving macrophage polarization toward the M2 phenotype and restoring immune homeostasis. These findings highlight MaR1 as a promising candidate for targeted immunomodulatory therapies in DKD.

Indexed as

Diabetic NephropathiesDocosahexaenoic AcidsMacrophagesAnimalsDiabetes Mellitus, ExperimentalMaleMiceMice, Inbred C57BLSpecialized Pro-Resolving Mediators7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidDocosahexaenoic Acidsdiabetic kidney diseaseimmune modulationmacrophage polarizationMaresin 1

Identifiers

PMID41887186
PMCPMC13140252

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.